Medivir AB (publ)
MVRBF · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.15 | 0.56 | 0.11 | 0.08 |
| FCF Yield | -23.81% | -8.23% | -19.99% | -24.56% |
| EV / EBITDA | -5.14 | -10.02 | -8.14 | -5.39 |
| Quality | ||||
| ROIC | -41.94% | -21.23% | -27.08% | -51.42% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 1.15 | 0.78 | 1.36 | 1.20 |
| Growth | ||||
| Revenue 3-Year CAGR | -31.88% | 43.05% | -16.39% | -38.02% |
| Free Cash Flow Growth | -109.71% | 19.76% | 59.43% | 54.01% |
| Safety | ||||
| Net Debt / EBITDA | -0.11 | 0.01 | -0.07 | -0.08 |
| Interest Coverage | -94.13 | -65.39 | -78.43 | -95.80 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |